Rani Therapeutics Inc. (RANI)
1.27
-0.01 (-0.78%)
At close: Jan 15, 2025, 11:38 AM
undefined% (undefined)
| Bid | 1.27 |
| Market Cap | 72.65M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.05 |
| PE Ratio (ttm) | -1.21 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.28 |
| Volume | 78,203 |
| Avg. Volume (20D) | 783,265 |
| Open | 1.30 |
| Previous Close | 1.28 |
| Day's Range | 1.27 - 1.31 |
| 52-Week Range | 1.24 - 8.75 |
| Beta | undefined |
About RANI
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-al...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 30, 2021
Employees 140
Stock Exchange NASDAQ
Ticker Symbol RANI
Website https://www.ranitherapeutics.com
Analyst Forecast
According to 6 analyst ratings, the average rating for RANI stock is "Buy." The 12-month stock price forecast is $9.5, which is an increase of 648.03% from the latest price.
Buy 83.33%
Hold 0.00%
Sell 0.00%
3 months ago ·
Source
-33.33%
Rani Therapeutics shares are trading lower after t...
Unlock content with
Pro Subscription
